HC Wainwright Issues Optimistic Estimate for CRDL Earnings

Cardiol Therapeutics Inc. (NASDAQ:CRDL) – Stock analysts at HC Wainwright increased their FY2024 earnings per share (EPS) estimates for shares of Cardiol Therapeutics in a research report issued on Wednesday, November 20th. HC Wainwright analyst V. Bernardino now expects that the company will earn ($0.38) per share for the year, up from their prior forecast of ($0.44). HC Wainwright currently has a “Buy” rating and a $9.00 target price on the stock. The consensus estimate for Cardiol Therapeutics’ current full-year earnings is ($0.36) per share. HC Wainwright also issued estimates for Cardiol Therapeutics’ Q4 2024 earnings at ($0.09) EPS and FY2025 earnings at ($0.34) EPS.

Cardiol Therapeutics Stock Up 2.5 %

Shares of NASDAQ CRDL opened at $1.62 on Friday. Cardiol Therapeutics has a 12-month low of $0.79 and a 12-month high of $3.12. The company has a market cap of $132.19 million, a P/E ratio of -4.04 and a beta of 0.91. The company has a current ratio of 2.49, a quick ratio of 2.49 and a debt-to-equity ratio of 0.01. The stock has a fifty day moving average price of $1.95 and a 200 day moving average price of $2.08.

Institutional Trading of Cardiol Therapeutics

Several large investors have recently added to or reduced their stakes in the stock. Wealth Enhancement Advisory Services LLC acquired a new stake in Cardiol Therapeutics in the 3rd quarter valued at $27,000. Townsquare Capital LLC acquired a new stake in shares of Cardiol Therapeutics during the third quarter valued at about $27,000. Jane Street Group LLC acquired a new stake in shares of Cardiol Therapeutics during the third quarter valued at about $29,000. Lion Street Advisors LLC grew its stake in shares of Cardiol Therapeutics by 7.9% during the third quarter. Lion Street Advisors LLC now owns 273,281 shares of the company’s stock valued at $544,000 after acquiring an additional 20,000 shares in the last quarter. Finally, Baader Bank Aktiengesellschaft acquired a new stake in shares of Cardiol Therapeutics during the second quarter valued at about $59,000. 12.49% of the stock is currently owned by institutional investors and hedge funds.

About Cardiol Therapeutics

Cardiol Therapeutics Inc, a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis.